Acadia Pharmaceuticals (ACAD) reports Q4 results in line with EPS loss estimates but beats on...


Acadia Pharmaceuticals (ACAD) reports Q4 results in line with EPS loss estimates but beats on revenue, largely due to the conclusion of its collaboration with Biovail in October 2010.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs